Dry Age-Related Macular Degeneration
Modern Care for a Progressive Disease
Dry AMD affects an estimated 19.8 million Americans and moves through three stages: early, intermediate, and advanced geographic atrophy. Your stage determines your treatment plan. Options now include AREDS2 supplements, FDA-approved complement-inhibitor injections for geographic atrophy, and Valeda photobiomodulation for earlier-stage disease. Our team evaluates and monitors dry AMD patients across Manhattan, Brooklyn, and Queens.
Dry age-related macular degeneration is not a single moment of vision loss. It is a slow, traceable biological process, and the science of slowing it has changed more in the past three years than it did in the previous twenty.
Your central vision depends on the macula, a small pigment-dense region of the retina responsible for fine detail, color, and reading. In dry AMD, the support cells beneath the macula gradually lose their ability to clear cellular waste, and yellow deposits called drusen accumulate. Over time, that failure leads to thinning, dysfunction, and in some patients, atrophy of the photoreceptors that capture light. Precision in identifying where a patient sits on that continuum is the entire clinical task.
For decades, the standard of care was watchful waiting plus AREDS2 vitamins, the formulation refined by the National Eye Institute and shown to reduce the risk of progression to advanced AMD by about 25% in patients with intermediate disease. That benefit is well-documented, and AREDS2 remains the foundation of every modern care plan.
But AREDS2 alone is no longer the most advanced version of dry AMD care, and at NY LASIK we do not stop the conversation there when newer, evidence-backed options exist. We serve patients across Manhattan, Brooklyn, and Queens, with a deep referral base in Brooklyn.
Modern dry AMD management combines imaging surveillance, nutritional therapy, complement-inhibitor injections for geographic atrophy, and photobiomodulation for earlier-stage disease, calibrated to where the disease actually is. Not a brochure of options. A care plan built on current evidence.
How Dry AMD Affects the Macula
The macula is the part of the retina responsible for the central vision you use to read, recognize faces, and drive. In dry AMD, the retinal pigment epithelium (RPE) cells beneath the photoreceptors gradually lose efficiency at clearing waste. Cellular debris accumulates between the RPE and Bruch’s membrane, forming the yellow deposits called drusen described by the American Academy of Ophthalmology.
Drusen alone do not always cause symptoms, but medium-to-large drusen signal that the macular environment is no longer stable. Research continues to identify the molecular drivers, with strong evidence that overactivation of the complement system, part of the innate immune response, contributes to RPE damage and photoreceptor death. That mechanism is the rationale behind the new generation of complement-inhibitor therapies reviewed in Clinical & Experimental Ophthalmology.
Dry AMD is a disease of failing cellular maintenance. Catching that failure early, while RPE cells still have function to preserve, changes what the next decade of vision looks like.
Stages of Dry AMD and What They Mean for Your Vision
Dry AMD does not present the same way in every patient. Ophthalmologists categorize the disease in three broad stages.
Early Dry AMD
Small drusen are visible on retinal imaging, but central vision is usually unaffected and patients often have no symptoms. The right plan at this stage is structured monitoring, lifestyle modification, and risk-factor management.
Intermediate Dry AMD
Larger drusen accumulate and pigment changes appear in the RPE. Some patients notice difficulty adjusting to low light, slower reading speed, or a need for brighter task lighting. This is the stage where AREDS2 supplementation, as established by the National Eye Institute, becomes the evidence-based foundation of care.
Advanced Dry AMD (Geographic Atrophy)
In geographic atrophy, regions of RPE and overlying photoreceptors die, producing well-demarcated areas of retinal cell loss visible on fundus autofluorescence imaging. It is the form of dry AMD most likely to produce noticeable central vision loss and the form for which intravitreal complement-inhibitor therapy is now approved. According to a BrightFocus Foundation summary, geographic atrophy accounts for roughly 20% of legal blindness in the United States and affects approximately one million Americans.
Knowing which stage you are in determines which treatment, monitoring schedule, and lifestyle plan is right for you.
The Dry Stage is a Treatment Window
Dry AMD can convert to wet AMD. When that happens, the complement inhibitor injections and photobiomodulation options available during the dry stage are no longer the primary focus. Anti-VEGF injections become the urgent priority, and the goal shifts from slowing progression to stopping active bleeding beneath the retina.
That is why the dry stage matters clinically, not just diagnostically. The treatments available now are not available at every stage. Acting during the window when RPE cells still have function to preserve is what changes the long-term outlook.
How We Evaluate and Monitor Dry AMD
A modern dry AMD evaluation goes well beyond a basic eye chart. Our team builds a full picture of your retina using:
- A dilated retinal examination
- Spectral-domain optical coherence tomography (SD-OCT) for near-cellular resolution imaging of retinal layers
- Fundus autofluorescence (FAF) to map areas of RPE stress and atrophy
- Color fundus photography to document drusen and pigment changes over time
- Visual acuity and, when appropriate, contrast sensitivity testing
- A baseline Amsler grid to document any existing central distortion
Once your stage is established, we set a surveillance schedule. Early dry AMD is usually seen annually. Intermediate patients are typically seen every six months. Patients with geographic atrophy or fellow-eye wet AMD often need closer follow-up. According to CDC Vision and Eye Health Surveillance System estimates, vision-threatening AMD prevalence rises sharply with age, which is why a stage-specific schedule matters more than a fixed yearly visit.
Treatment Options for Dry AMD
There is no cure for dry AMD, but there is now a real spectrum of evidence-based treatments. The right combination depends on stage, anatomy, and patient priorities.
AREDS2 Nutritional Therapy
The AREDS and AREDS2 trials, funded by the National Eye Institute, established that a specific high-dose antioxidant and zinc formulation reduces the risk of progression from intermediate to advanced AMD by approximately 25%. The current AREDS2 formula replaces beta-carotene with lutein and zeaxanthin to avoid lung cancer risk in smokers and former smokers, while preserving the protective effect on AMD progression. AREDS2 does not prevent AMD onset and offers no benefit in early-stage disease, which is why we recommend it based on your specific stage. The Journal of Ophthalmic & Vision Research summarizes the supporting evidence in depth.
Syfovre and Izervay for Geographic Atrophy
In 2023, the FDA approved the first treatments for geographic atrophy. Syfovre (pegcetacoplan), a complement C3 inhibitor, received FDA approval in February 2023 based on the OAKS and DERBY phase 3 trials, which showed up to a 36% reduction in geographic atrophy lesion growth with monthly dosing in DERBY between months 18 and 24. Izervay (avacincaptad pegol), a complement C5 inhibitor, was approved later that year. A post hoc analysis of the GATHER1 and GATHER2 trials in Ophthalmology Retina showed Izervay reduced the risk of persistent vision loss compared with sham over 12 months.
Both drugs are intravitreal injections intended to slow progression, not restore vision, and they carry real risks. The American Academy of Ophthalmology has flagged concerns about retinal vasculitis and increased risk of conversion to wet AMD with these agents. Candidacy is individualized, and our team coordinates evaluation with our retina specialist, Dr. Moshe M. Szlechter.
Photobiomodulation With the Valeda Light Delivery System
For patients with early to intermediate dry AMD who are not yet candidates for intravitreal therapy, photobiomodulation (PBM) is a non-invasive option. The LIGHTSITE III randomized controlled trial in Retina found that patients treated with multiwavelength PBM using the Valeda Light Delivery System gained a mean of 5.4 ETDRS letters of best-corrected visual acuity at 13 months and showed a significant reduction in new-onset geographic atrophy compared with sham. A typical course involves nine in-office sessions over three to four weeks, with no recovery time.
Learn more about Valeda Light Therapy
Lifestyle and Risk Reduction
Modifiable risk factors include smoking, uncontrolled hypertension, cardiovascular disease, obesity, and a diet low in leafy greens and oily fish. We work with you on UV protection, smoking cessation, blood pressure optimization, and a Mediterranean diet. These complement, but do not replace, stage-specific therapy.
The Amsler grid is a simple square of lines with a central dot, used at home to detect distortion (metamorphopsia) or blind spots (scotomas) that may signal conversion from dry to wet AMD. The American Academy of Ophthalmology recommends daily one-eye-at-a-time monitoring at a reading distance of roughly 12 to 15 inches with any usual reading correction.
The grid is a screening aid, not a diagnostic test. A 2023 systematic review summarized by the American Academy of Ophthalmology reported 67% sensitivity and 99% specificity for detecting neovascular AMD, meaning it catches many but not all conversions. We provide every dry AMD patient with a grid and ask them to call us immediately if any line appears wavy, blurred, or missing.
Who Is a Candidate for Dry AMD Care
If you are over 50, have a family history of macular degeneration, smoke or used to smoke, have cardiovascular disease, or have noticed a subtle change in your central vision, an evaluation is appropriate. Caucasian patients and women have somewhat higher risk, but no group is exempt.
Specific candidacy depends on the treatment:
- AREDS2 supplementation is recommended for intermediate dry AMD or advanced AMD in one eye, not for early disease.
- Complement-inhibitor injections (Syfovre, Izervay) are indicated only for confirmed geographic atrophy.
- Valeda photobiomodulation is FDA-authorized for early to intermediate dry AMD with measurable visual function preserved.
Candidacy is a clinical decision made after imaging and examination, not a self-assessment.
Why Choose NY LASIK for Dry AMD Care
NY LASIK is led by Leonard Bley, MD, FACS, an internationally recognized leader in cataract and refractive surgery with over 30 years of experience and more than 100,000 procedures performed. Dr. Bley has been involved in refractive surgery since 1989, before LASIK received FDA approval, and is board-certified by the American Board of Ophthalmology. He carries the FACS designation and is EVO-Certified.
Dr. Bley founded NY LASIK as part of the Laser and Microsurgery Institute to deliver an integrated approach to vision care, where refractive surgery, cataract surgery, glaucoma management, and retinal disease evaluation happen under one practice umbrella. For dry AMD specifically, our team coordinates with Dr. Moshe M. Szlechter, MD, our in-house retina surgeon, and our optometric team for follow-up imaging and home-monitoring support.
When a patient arrives with a question about drusen, blurred reading vision, or a recent AMD diagnosis from another provider, we image, stage, treat, and follow that disease across the rest of your eye care. You are not bounced between unconnected specialists. We have cared for patients across Manhattan, Brooklyn, and Queens for decades, with a particularly strong base in Brooklyn. Trusted by athletes, physicians, and patients who research before they decide.
No, there is no cure for dry AMD. There are now evidence-based treatments that slow progression: AREDS2 supplementation, FDA-approved complement inhibitors for geographic atrophy, and photobiomodulation for earlier-stage disease. The goal of treatment is to preserve the vision you have, not to restore vision already lost.
Dry AMD is the more common form, accounting for roughly 90% of cases, and involves gradual thinning of the macula with accumulation of drusen. Wet AMD occurs when abnormal blood vessels grow beneath the retina and leak fluid or blood, causing rapid central vision loss. Dry AMD can convert to wet AMD, which is why daily home monitoring matters. Wet AMD is treated with anti-VEGF injections such as ranibizumab, aflibercept, or bevacizumab.
No. AREDS2 vitamins reduce the risk of progression from intermediate AMD to advanced AMD by about 25%. They do not prevent AMD onset, and the National Eye Institute does not recommend them for patients without AMD or with early-stage disease.
Both were FDA-approved based on phase 3 data showing reduced geographic atrophy lesion growth, but they carry real risks. The American Academy of Ophthalmology has flagged concerns about retinal vasculitis with Syfovre and an increased rate of conversion to wet AMD with both agents. The decision depends on your imaging, the location of the atrophy, the rate of progression, and a careful discussion with our retina team.
Daily, one eye at a time, ideally as part of your morning routine. If you notice any new wavy lines, dark spots, or missing areas while focusing on the central dot, call our office promptly. Conversion from dry to wet AMD is one of the few moments in AMD care where rapid intervention changes the outcome.
Progression varies significantly between patients. Many people with early dry AMD remain stable for years, while others advance to geographic atrophy more quickly. Smoking, untreated hypertension, and a family history of advanced AMD are associated with faster progression. SD-OCT and fundus autofluorescence imaging is the most reliable way to track your individual rate.
Source Index
- American Academy of Ophthalmology. “What Is Macular Degeneration?” https://www.aao.org/eye-health/diseases/amd-macular-degeneration
- Girgis S, Lee LR. “Treatment of dry age-related macular degeneration: A review.” Clinical & Experimental Ophthalmology, 2023; 51(8):835-852. https://doi.org/10.1111/ceo.14294
- National Eye Institute. “About AREDS and AREDS2.” https://www.nei.nih.gov/eye-health-information/clinical-trials/age-related-eye-disease-studies-aredsareds2/about-areds-and-areds2
- National Eye Institute. “AREDS/AREDS2 Frequently Asked Questions.” https://www.nei.nih.gov/eye-health-information/clinical-trials/age-related-eye-disease-studies-aredsareds2/aredsareds2-frequently-asked-questions
- BrightFocus Foundation. “Second Geographic Atrophy Treatment Receives FDA Approval.” https://www.brightfocus.org/news/second-geographic-atrophy-treatment-receives-fda-approval/
- CDC. “VEHSS Modeled Estimates: Age-Related Macular Degeneration (AMD).” https://www.cdc.gov/vision-health-data/prevalence-estimates/amd-prevalence.html
- Apellis Pharmaceuticals Investor News. “FDA Approves SYFOVRE (pegcetacoplan injection).” https://investors.apellis.com/news-releases/news-release-details/fda-approves-syfovretm-pegcetacoplan-injection-first-and-only
- Danzig CJ, Khanani AM, Kaiser PK, et al. “Vision Loss Reduction with Avacincaptad Pegol for Geographic Atrophy: A 12-Month Post Hoc Analysis of the GATHER1 and GATHER2 Trials.” Ophthalmology Retina, 2024;8(11):1052-1060. https://doi.org/10.1016/j.oret.2024.04.023
- American Academy of Ophthalmology. “What to Know About Syfovre and Izervay for Geographic Atrophy.” https://www.aao.org/eye-health/tips-prevention/syfovre-izervay-geographic-atrophy-amd-macular-deg
- Boyer D, Hu A, Warrow D, et al. “LIGHTSITE III: 13-Month Efficacy and Safety Evaluation of Multiwavelength Photobiomodulation in Nonexudative (Dry) Age-Related Macular Degeneration Using the Lumithera Valeda Light Delivery System.” Retina, 2024;44(3):487-497. https://doi.org/10.1097/IAE.0000000000003980
- American Academy of Ophthalmology. “All About the Amsler Grid and Daily Vision Checks for AMD.” https://www.aao.org/eye-health/tips-prevention/facts-about-amsler-grid-daily-vision-test
- American Academy of Ophthalmology, Editor’s Choice. “Amsler grid may not be as reliable as once thought for self-monitoring AMD.” https://www.aao.org/education/editors-choice/amsler-grid-may-not-be-as-reliable-as-once-thought
- Hobbs RP, Bernstein PS. “Nutrient Supplementation for Age-related Macular Degeneration, Cataract, and Dry Eye.” Journal of Ophthalmic & Vision Research, 2014;9(4):487-493. https://pmc.ncbi.nlm.nih.gov/articles/PMC4329711/
The content on this page was authored and medically reviewed by Dr. Leonard M. Bley, MD, FACS, founder of NY LASIK and Surgical Director of Laser and Microsurgery Institute. Dr. Bley is an internationally recognized, board-certified refractive and cataract surgeon with over 35 years of clinical experience and more than 30,000 vision correction procedures performed across our Manhattan, Brooklyn, and Queens offices. A Fellow of the American Academy of Ophthalmology and member of the American College of Eye Surgeons, he trained at Manhattan Eye, Ear and Throat Hospital and completed fellowship training at New York University Hospital, with hospital affiliations at NYU Langone and Staten Island University Hospital. By combining decades of surgical expertise with a commitment to evidence-based, patient-centered care, our team ensures all content on this site reflects the most current and accurate information in refractive surgery, cataract care, and advanced eye health.